ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT06581861
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases.
PREVENT protocol is specific for asymptomatic participants who are genetically at risk for ALS. The participants will be followed for up to 36 months (3 years), and will include 4 in-person on-site visits once a year and 6 off-site(remote) visits once in 4 months. The study includes collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once in 4 months. Participants may also provide optional Cerebrospinal Fluid (CSF) samples.The participants may also opt into a sub-study if they are interested in genetic testing for ALS causative genes. The sub-study will involve a minimum of 3 visits over a course of 2-3 months. This will include a screening/pre-test genetic counseling visit, a return of genetic results and a post-test counseling visit.
Interested in participating?
Request Info18 year and older
All sexes
Observational
CHALS-CCT, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria
for Participants Undergoing Optional Lumbar Puncture
Inclusion criteria
for Genetic Testing Results Sub-study
Time frame: Baseline, 4, 8, 12,16,20, 24, 28, 32 and 36 months form baseline
Questions to identify development of symptoms related to ALS
Time frame: Once at Month 1 from Baseline
Questionnaires completed by participants that includes questions about non-medical factors that affect health outcomes
Time frame: at Baseline, 12, 24 and 36 months from baseline
ECAS is a multi-domain assessment administered by study staff, to evaluate different aspects of cognitive function
Time frame: at Baseline, 12, 24 and 36 months from baseline
CDR-FTLD is a global assessment scale that evaluates severity of impairment across multiple domains in patients with Frontotemporal dementia (FTLD) spectrum disorders.
Time frame: at Baseline, 12, 24 and 36 months from baseline
HHD is used as a quantitative measure of muscle strength. This will involve testing of the bilateral deltoid, biceps, triceps, wrist extension, FDI, ADM, APB, hip extension, quadriceps, hamstring, TA and grip strength.
Time frame: at Baseline, and at months 4,8,12,16,20,24,28,32 and 36 months
Participants will be asked to record voice samples at home once a month using a digital application installed on their device.
Time frame: at Baseline, 12, 24 and 36 months from baseline
It is the change in respiratory function over time as measured by Slow Vital Capacity (SVC).
Contact information is provided by the study sponsor or research team.
St. Joseph's Hospital and Medical Center, Phoenix
Other
PREVENT ALL ALS - Longitudinal Biomarker Study for Participants Who Are Genetically at Risk for Amyotrophic Lateral Sclerosis (ALS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04363684
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06578195
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06284161
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Clermont-Ferrand, France
View Trial DetailsNCT03225144
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Bethesda, Maryland, United States
View Trial Details